Market Research Report
Market Access, Pricing and Reimbursement of Oncology Medicines in the 5EU
|Published by||GlobalData||Product code||721736|
|Published||Content info||162 Pages
Delivery time: 1-2 business days
|Market Access, Pricing and Reimbursement of Oncology Medicines in the 5EU|
|Published: September 10, 2018||Content info: 162 Pages||
Market access of oncology medicines is increasingly challenging due to the rising cost of new and innovative medicines, more stringent scientific and value assessments and economic pressures on national budgets and health systems. Although, 5EU markets have implemented patient access schemed to ensure early access to innovative oncology medicines with high unmet need, the increasing requirements for improved clinical benefits and better cost-effectiveness of medicines has resulted in more stringent pricing and reimbursement of medicines leading to access issues such as delays in patient access due to negotiations.
In this report, GlobalData provides an overview of market access, pricing and reimbursement in the 5EU (France, Germany, Italy, Spain and UK) including key KOL and payers perspectives throughout. KOLs and Payers also provide insights into the market access trends, challenges, drivers and barriers. KOLs and Payers also provide insights on unmet needs in oncology and overall current and future outlook.
The report combines key opinion leader and payer insight with in-house analyst expertise and research to provide an insight-rich look at market access in the 5EU. Components of the report include -